Angelini Ventures
RougeTx is a preclinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to restore vascular integrity by targeting pericyte dysfunction, with its lead program RTX-001 advancing toward first-in-human development for hereditary hemorrhagic telangiectasia (HHT).
Related news:
Angelini Ventures co-leads $58M Series A in RougeTx to advance first-in-class HHT treatment